These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 36920662)

  • 1. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
    Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
    Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Zhang B; Long EF
    Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of ribociclib plus letrozole
    Buehler AM; Castilho G; Dionne PA; Stefani S
    Ther Adv Med Oncol; 2021; 13():17588359211000593. PubMed ID: 33948121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
    Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
    J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
    Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom.
    Suri G; Chandiwana D; Lee A; Mistry R
    J Health Econ Outcomes Res; 2019; 6(2):20-31. PubMed ID: 32685577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation.
    Elazzazy S; Al-Ziftawi NH; Mohamed Ibrahim MI; Bujassoum S; Hamad A
    Front Oncol; 2024; 14():1413676. PubMed ID: 39114308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
    Berrios K; Burum A; Jeong E; Zhong L
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.
    Sra MS; Sasi A; Batra A; Bakhshi S; Ganguly S
    JCO Glob Oncol; 2024 Jul; 10():e2300433. PubMed ID: 39024528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.
    Galve-Calvo E; González-Haba E; Gostkorzewicz J; Martínez I; Pérez-Mitru A
    Clinicoecon Outcomes Res; 2018; 10():773-790. PubMed ID: 30532569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis.
    Zeng N; Han J; Liu Z; He J; Tian K; Chen N
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2- breast cancer in Mexico.
    Molina-Jaimes M; Galindo-González A; Verduzco-Aguirre HC; Bautista-Arredondo S; Reyes-Terán G; Soto-Perez-de-Celis E
    Clin Transl Oncol; 2024 Jan; 26(1):239-244. PubMed ID: 37329428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
    Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
    J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer.
    Hong J; Chen T; Ouyang L; Du N; Li A; Zhou Z; Zhang H; Xia Z; Meng J
    Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):559-566. PubMed ID: 38470447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.